Pharma & Healthcare
Global Hypertension Drug Market Research Report 2025
- Sep 09, 25
- ID: 497010
- Pages: 122
- Figures: 119
- Views: 4
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypertension Drug.
The Hypertension Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hypertension Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hypertension Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Actelion Ltd.
Alvogen
AstraZeneca Plc
Bayer AG
Bellerophon Therapeutics, Inc
Boehringer Ingelheim
Boryung Pharmaceutical Co.,Ltd
Bristol-Myers Squibb and Company,
Daiichi Sankyo Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc
HanAll Biopharma Co., Ltd
Hanmi Pharmaceutical Co., Ltd
Johnson & Johnson Ltd
JW Pharmaceutical Corporation (Choongwae Pharma)
Kyowa Kirin Co., Ltd
Lupin Limited
Merck & Co.
Noden Pharma DAC
Novartis AG
Pfizer Inc
Ranbaxy Laboratories Limited
Sanofi S.A
Lung Biotechnology PBC
Nippon Shinyaku Co. Ltd
Novartis AG
Segment by Type
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Segment by Application
Hospital
Private Clinic
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hypertension Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
This report aims to provide a comprehensive presentation of the global market for Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypertension Drug.
The Hypertension Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hypertension Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hypertension Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Actelion Ltd.
Alvogen
AstraZeneca Plc
Bayer AG
Bellerophon Therapeutics, Inc
Boehringer Ingelheim
Boryung Pharmaceutical Co.,Ltd
Bristol-Myers Squibb and Company,
Daiichi Sankyo Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc
HanAll Biopharma Co., Ltd
Hanmi Pharmaceutical Co., Ltd
Johnson & Johnson Ltd
JW Pharmaceutical Corporation (Choongwae Pharma)
Kyowa Kirin Co., Ltd
Lupin Limited
Merck & Co.
Noden Pharma DAC
Novartis AG
Pfizer Inc
Ranbaxy Laboratories Limited
Sanofi S.A
Lung Biotechnology PBC
Nippon Shinyaku Co. Ltd
Novartis AG
Segment by Type
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Segment by Application
Hospital
Private Clinic
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hypertension Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Hypertension Drug Market Overview
1.1 Product Definition
1.2 Hypertension Drug by Type
1.2.1 Global Hypertension Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Calcium Channel Blockers
1.2.3 Diuretics
1.2.4 Beta Blockers Vasodilators
1.2.5 Angiotensin Converting Enzyme Inhibitors
1.2.6 Alpha Blockers
1.2.7 Angiotensin Receptor Blockers
1.2.8 Renin Inhibitors
1.3 Hypertension Drug by Application
1.3.1 Global Hypertension Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Private Clinic
1.3.4 Others
1.4 Global Hypertension Drug Market Size Estimates and Forecasts
1.4.1 Global Hypertension Drug Revenue 2020-2031
1.4.2 Global Hypertension Drug Sales 2020-2031
1.4.3 Global Hypertension Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hypertension Drug Market Competition by Manufacturers
2.1 Global Hypertension Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hypertension Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hypertension Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hypertension Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hypertension Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hypertension Drug, Product Type & Application
2.7 Global Key Manufacturers of Hypertension Drug, Date of Enter into This Industry
2.8 Global Hypertension Drug Market Competitive Situation and Trends
2.8.1 Global Hypertension Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hypertension Drug Players Market Share by Revenue
2.8.3 Global Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hypertension Drug Market Scenario by Region
3.1 Global Hypertension Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hypertension Drug Sales by Region: 2020-2031
3.2.1 Global Hypertension Drug Sales by Region: 2020-2025
3.2.2 Global Hypertension Drug Sales by Region: 2026-2031
3.3 Global Hypertension Drug Revenue by Region: 2020-2031
3.3.1 Global Hypertension Drug Revenue by Region: 2020-2025
3.3.2 Global Hypertension Drug Revenue by Region: 2026-2031
3.4 North America Hypertension Drug Market Facts & Figures by Country
3.4.1 North America Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hypertension Drug Sales by Country (2020-2031)
3.4.3 North America Hypertension Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hypertension Drug Market Facts & Figures by Country
3.5.1 Europe Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hypertension Drug Sales by Country (2020-2031)
3.5.3 Europe Hypertension Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hypertension Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Hypertension Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hypertension Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Hypertension Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hypertension Drug Market Facts & Figures by Country
3.7.1 Latin America Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hypertension Drug Sales by Country (2020-2031)
3.7.3 Latin America Hypertension Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hypertension Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hypertension Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hypertension Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hypertension Drug Sales by Type (2020-2031)
4.1.1 Global Hypertension Drug Sales by Type (2020-2025)
4.1.2 Global Hypertension Drug Sales by Type (2026-2031)
4.1.3 Global Hypertension Drug Sales Market Share by Type (2020-2031)
4.2 Global Hypertension Drug Revenue by Type (2020-2031)
4.2.1 Global Hypertension Drug Revenue by Type (2020-2025)
4.2.2 Global Hypertension Drug Revenue by Type (2026-2031)
4.2.3 Global Hypertension Drug Revenue Market Share by Type (2020-2031)
4.3 Global Hypertension Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hypertension Drug Sales by Application (2020-2031)
5.1.1 Global Hypertension Drug Sales by Application (2020-2025)
5.1.2 Global Hypertension Drug Sales by Application (2026-2031)
5.1.3 Global Hypertension Drug Sales Market Share by Application (2020-2031)
5.2 Global Hypertension Drug Revenue by Application (2020-2031)
5.2.1 Global Hypertension Drug Revenue by Application (2020-2025)
5.2.2 Global Hypertension Drug Revenue by Application (2026-2031)
5.2.3 Global Hypertension Drug Revenue Market Share by Application (2020-2031)
5.3 Global Hypertension Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Actelion Ltd.
6.1.1 Actelion Ltd. Company Information
6.1.2 Actelion Ltd. Description and Business Overview
6.1.3 Actelion Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Actelion Ltd. Hypertension Drug Product Portfolio
6.1.5 Actelion Ltd. Recent Developments/Updates
6.2 Alvogen
6.2.1 Alvogen Company Information
6.2.2 Alvogen Description and Business Overview
6.2.3 Alvogen Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alvogen Hypertension Drug Product Portfolio
6.2.5 Alvogen Recent Developments/Updates
6.3 AstraZeneca Plc
6.3.1 AstraZeneca Plc Company Information
6.3.2 AstraZeneca Plc Description and Business Overview
6.3.3 AstraZeneca Plc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Plc Hypertension Drug Product Portfolio
6.3.5 AstraZeneca Plc Recent Developments/Updates
6.4 Bayer AG
6.4.1 Bayer AG Company Information
6.4.2 Bayer AG Description and Business Overview
6.4.3 Bayer AG Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bayer AG Hypertension Drug Product Portfolio
6.4.5 Bayer AG Recent Developments/Updates
6.5 Bellerophon Therapeutics, Inc
6.5.1 Bellerophon Therapeutics, Inc Company Information
6.5.2 Bellerophon Therapeutics, Inc Description and Business Overview
6.5.3 Bellerophon Therapeutics, Inc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bellerophon Therapeutics, Inc Hypertension Drug Product Portfolio
6.5.5 Bellerophon Therapeutics, Inc Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Company Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Boehringer Ingelheim Hypertension Drug Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Boryung Pharmaceutical Co.,Ltd
6.7.1 Boryung Pharmaceutical Co.,Ltd Company Information
6.7.2 Boryung Pharmaceutical Co.,Ltd Description and Business Overview
6.7.3 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product Portfolio
6.7.5 Boryung Pharmaceutical Co.,Ltd Recent Developments/Updates
6.8 Bristol-Myers Squibb and Company,
6.8.1 Bristol-Myers Squibb and Company, Company Information
6.8.2 Bristol-Myers Squibb and Company, Description and Business Overview
6.8.3 Bristol-Myers Squibb and Company, Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bristol-Myers Squibb and Company, Hypertension Drug Product Portfolio
6.8.5 Bristol-Myers Squibb and Company, Recent Developments/Updates
6.9 Daiichi Sankyo Company
6.9.1 Daiichi Sankyo Company Company Information
6.9.2 Daiichi Sankyo Company Description and Business Overview
6.9.3 Daiichi Sankyo Company Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Daiichi Sankyo Company Hypertension Drug Product Portfolio
6.9.5 Daiichi Sankyo Company Recent Developments/Updates
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Company Information
6.10.2 Eli Lilly and Company Description and Business Overview
6.10.3 Eli Lilly and Company Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly and Company Hypertension Drug Product Portfolio
6.10.5 Eli Lilly and Company Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd.
6.11.1 F. Hoffmann-La Roche Ltd. Company Information
6.11.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 F. Hoffmann-La Roche Ltd. Hypertension Drug Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.12 Gilead Sciences, Inc
6.12.1 Gilead Sciences, Inc Company Information
6.12.2 Gilead Sciences, Inc Description and Business Overview
6.12.3 Gilead Sciences, Inc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Gilead Sciences, Inc Hypertension Drug Product Portfolio
6.12.5 Gilead Sciences, Inc Recent Developments/Updates
6.13 HanAll Biopharma Co., Ltd
6.13.1 HanAll Biopharma Co., Ltd Company Information
6.13.2 HanAll Biopharma Co., Ltd Description and Business Overview
6.13.3 HanAll Biopharma Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 HanAll Biopharma Co., Ltd Hypertension Drug Product Portfolio
6.13.5 HanAll Biopharma Co., Ltd Recent Developments/Updates
6.14 Hanmi Pharmaceutical Co., Ltd
6.14.1 Hanmi Pharmaceutical Co., Ltd Company Information
6.14.2 Hanmi Pharmaceutical Co., Ltd Description and Business Overview
6.14.3 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product Portfolio
6.14.5 Hanmi Pharmaceutical Co., Ltd Recent Developments/Updates
6.15 Johnson & Johnson Ltd
6.15.1 Johnson & Johnson Ltd Company Information
6.15.2 Johnson & Johnson Ltd Description and Business Overview
6.15.3 Johnson & Johnson Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Johnson & Johnson Ltd Hypertension Drug Product Portfolio
6.15.5 Johnson & Johnson Ltd Recent Developments/Updates
6.16 JW Pharmaceutical Corporation (Choongwae Pharma)
6.16.1 JW Pharmaceutical Corporation (Choongwae Pharma) Company Information
6.16.2 JW Pharmaceutical Corporation (Choongwae Pharma) Description and Business Overview
6.16.3 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.16.4 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product Portfolio
6.16.5 JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments/Updates
6.17 Kyowa Kirin Co., Ltd
6.17.1 Kyowa Kirin Co., Ltd Company Information
6.17.2 Kyowa Kirin Co., Ltd Description and Business Overview
6.17.3 Kyowa Kirin Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Kyowa Kirin Co., Ltd Hypertension Drug Product Portfolio
6.17.5 Kyowa Kirin Co., Ltd Recent Developments/Updates
6.18 Lupin Limited
6.18.1 Lupin Limited Company Information
6.18.2 Lupin Limited Description and Business Overview
6.18.3 Lupin Limited Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Lupin Limited Hypertension Drug Product Portfolio
6.18.5 Lupin Limited Recent Developments/Updates
6.19 Merck & Co.
6.19.1 Merck & Co. Company Information
6.19.2 Merck & Co. Description and Business Overview
6.19.3 Merck & Co. Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Merck & Co. Hypertension Drug Product Portfolio
6.19.5 Merck & Co. Recent Developments/Updates
6.20 Noden Pharma DAC
6.20.1 Noden Pharma DAC Company Information
6.20.2 Noden Pharma DAC Description and Business Overview
6.20.3 Noden Pharma DAC Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Noden Pharma DAC Hypertension Drug Product Portfolio
6.20.5 Noden Pharma DAC Recent Developments/Updates
6.21 Novartis AG
6.21.1 Novartis AG Company Information
6.21.2 Novartis AG Description and Business Overview
6.21.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Novartis AG Hypertension Drug Product Portfolio
6.21.5 Novartis AG Recent Developments/Updates
6.22 Pfizer Inc
6.22.1 Pfizer Inc Company Information
6.22.2 Pfizer Inc Description and Business Overview
6.22.3 Pfizer Inc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Pfizer Inc Hypertension Drug Product Portfolio
6.22.5 Pfizer Inc Recent Developments/Updates
6.23 Ranbaxy Laboratories Limited
6.23.1 Ranbaxy Laboratories Limited Company Information
6.23.2 Ranbaxy Laboratories Limited Description and Business Overview
6.23.3 Ranbaxy Laboratories Limited Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Ranbaxy Laboratories Limited Hypertension Drug Product Portfolio
6.23.5 Ranbaxy Laboratories Limited Recent Developments/Updates
6.24 Sanofi S.A
6.24.1 Sanofi S.A Company Information
6.24.2 Sanofi S.A Description and Business Overview
6.24.3 Sanofi S.A Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Sanofi S.A Hypertension Drug Product Portfolio
6.24.5 Sanofi S.A Recent Developments/Updates
6.25 Lung Biotechnology PBC
6.25.1 Lung Biotechnology PBC Company Information
6.25.2 Lung Biotechnology PBC Description and Business Overview
6.25.3 Lung Biotechnology PBC Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Lung Biotechnology PBC Hypertension Drug Product Portfolio
6.25.5 Lung Biotechnology PBC Recent Developments/Updates
6.26 Nippon Shinyaku Co. Ltd
6.26.1 Nippon Shinyaku Co. Ltd Company Information
6.26.2 Nippon Shinyaku Co. Ltd Description and Business Overview
6.26.3 Nippon Shinyaku Co. Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Nippon Shinyaku Co. Ltd Hypertension Drug Product Portfolio
6.26.5 Nippon Shinyaku Co. Ltd Recent Developments/Updates
6.27 Novartis AG
6.27.1 Novartis AG Company Information
6.27.2 Novartis AG Description and Business Overview
6.27.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.27.4 Novartis AG Hypertension Drug Product Portfolio
6.27.5 Novartis AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hypertension Drug Industry Chain Analysis
7.2 Hypertension Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hypertension Drug Production Mode & Process Analysis
7.4 Hypertension Drug Sales and Marketing
7.4.1 Hypertension Drug Sales Channels
7.4.2 Hypertension Drug Distributors
7.5 Hypertension Drug Customer Analysis
8 Hypertension Drug Market Dynamics
8.1 Hypertension Drug Industry Trends
8.2 Hypertension Drug Market Drivers
8.3 Hypertension Drug Market Challenges
8.4 Hypertension Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Hypertension Drug by Type
1.2.1 Global Hypertension Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Calcium Channel Blockers
1.2.3 Diuretics
1.2.4 Beta Blockers Vasodilators
1.2.5 Angiotensin Converting Enzyme Inhibitors
1.2.6 Alpha Blockers
1.2.7 Angiotensin Receptor Blockers
1.2.8 Renin Inhibitors
1.3 Hypertension Drug by Application
1.3.1 Global Hypertension Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Private Clinic
1.3.4 Others
1.4 Global Hypertension Drug Market Size Estimates and Forecasts
1.4.1 Global Hypertension Drug Revenue 2020-2031
1.4.2 Global Hypertension Drug Sales 2020-2031
1.4.3 Global Hypertension Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hypertension Drug Market Competition by Manufacturers
2.1 Global Hypertension Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hypertension Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hypertension Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hypertension Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hypertension Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hypertension Drug, Product Type & Application
2.7 Global Key Manufacturers of Hypertension Drug, Date of Enter into This Industry
2.8 Global Hypertension Drug Market Competitive Situation and Trends
2.8.1 Global Hypertension Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hypertension Drug Players Market Share by Revenue
2.8.3 Global Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hypertension Drug Market Scenario by Region
3.1 Global Hypertension Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hypertension Drug Sales by Region: 2020-2031
3.2.1 Global Hypertension Drug Sales by Region: 2020-2025
3.2.2 Global Hypertension Drug Sales by Region: 2026-2031
3.3 Global Hypertension Drug Revenue by Region: 2020-2031
3.3.1 Global Hypertension Drug Revenue by Region: 2020-2025
3.3.2 Global Hypertension Drug Revenue by Region: 2026-2031
3.4 North America Hypertension Drug Market Facts & Figures by Country
3.4.1 North America Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hypertension Drug Sales by Country (2020-2031)
3.4.3 North America Hypertension Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hypertension Drug Market Facts & Figures by Country
3.5.1 Europe Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hypertension Drug Sales by Country (2020-2031)
3.5.3 Europe Hypertension Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hypertension Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Hypertension Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hypertension Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Hypertension Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hypertension Drug Market Facts & Figures by Country
3.7.1 Latin America Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hypertension Drug Sales by Country (2020-2031)
3.7.3 Latin America Hypertension Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hypertension Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hypertension Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hypertension Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hypertension Drug Sales by Type (2020-2031)
4.1.1 Global Hypertension Drug Sales by Type (2020-2025)
4.1.2 Global Hypertension Drug Sales by Type (2026-2031)
4.1.3 Global Hypertension Drug Sales Market Share by Type (2020-2031)
4.2 Global Hypertension Drug Revenue by Type (2020-2031)
4.2.1 Global Hypertension Drug Revenue by Type (2020-2025)
4.2.2 Global Hypertension Drug Revenue by Type (2026-2031)
4.2.3 Global Hypertension Drug Revenue Market Share by Type (2020-2031)
4.3 Global Hypertension Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hypertension Drug Sales by Application (2020-2031)
5.1.1 Global Hypertension Drug Sales by Application (2020-2025)
5.1.2 Global Hypertension Drug Sales by Application (2026-2031)
5.1.3 Global Hypertension Drug Sales Market Share by Application (2020-2031)
5.2 Global Hypertension Drug Revenue by Application (2020-2031)
5.2.1 Global Hypertension Drug Revenue by Application (2020-2025)
5.2.2 Global Hypertension Drug Revenue by Application (2026-2031)
5.2.3 Global Hypertension Drug Revenue Market Share by Application (2020-2031)
5.3 Global Hypertension Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Actelion Ltd.
6.1.1 Actelion Ltd. Company Information
6.1.2 Actelion Ltd. Description and Business Overview
6.1.3 Actelion Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Actelion Ltd. Hypertension Drug Product Portfolio
6.1.5 Actelion Ltd. Recent Developments/Updates
6.2 Alvogen
6.2.1 Alvogen Company Information
6.2.2 Alvogen Description and Business Overview
6.2.3 Alvogen Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alvogen Hypertension Drug Product Portfolio
6.2.5 Alvogen Recent Developments/Updates
6.3 AstraZeneca Plc
6.3.1 AstraZeneca Plc Company Information
6.3.2 AstraZeneca Plc Description and Business Overview
6.3.3 AstraZeneca Plc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Plc Hypertension Drug Product Portfolio
6.3.5 AstraZeneca Plc Recent Developments/Updates
6.4 Bayer AG
6.4.1 Bayer AG Company Information
6.4.2 Bayer AG Description and Business Overview
6.4.3 Bayer AG Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bayer AG Hypertension Drug Product Portfolio
6.4.5 Bayer AG Recent Developments/Updates
6.5 Bellerophon Therapeutics, Inc
6.5.1 Bellerophon Therapeutics, Inc Company Information
6.5.2 Bellerophon Therapeutics, Inc Description and Business Overview
6.5.3 Bellerophon Therapeutics, Inc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bellerophon Therapeutics, Inc Hypertension Drug Product Portfolio
6.5.5 Bellerophon Therapeutics, Inc Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Company Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Boehringer Ingelheim Hypertension Drug Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Boryung Pharmaceutical Co.,Ltd
6.7.1 Boryung Pharmaceutical Co.,Ltd Company Information
6.7.2 Boryung Pharmaceutical Co.,Ltd Description and Business Overview
6.7.3 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product Portfolio
6.7.5 Boryung Pharmaceutical Co.,Ltd Recent Developments/Updates
6.8 Bristol-Myers Squibb and Company,
6.8.1 Bristol-Myers Squibb and Company, Company Information
6.8.2 Bristol-Myers Squibb and Company, Description and Business Overview
6.8.3 Bristol-Myers Squibb and Company, Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bristol-Myers Squibb and Company, Hypertension Drug Product Portfolio
6.8.5 Bristol-Myers Squibb and Company, Recent Developments/Updates
6.9 Daiichi Sankyo Company
6.9.1 Daiichi Sankyo Company Company Information
6.9.2 Daiichi Sankyo Company Description and Business Overview
6.9.3 Daiichi Sankyo Company Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Daiichi Sankyo Company Hypertension Drug Product Portfolio
6.9.5 Daiichi Sankyo Company Recent Developments/Updates
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Company Information
6.10.2 Eli Lilly and Company Description and Business Overview
6.10.3 Eli Lilly and Company Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly and Company Hypertension Drug Product Portfolio
6.10.5 Eli Lilly and Company Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd.
6.11.1 F. Hoffmann-La Roche Ltd. Company Information
6.11.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 F. Hoffmann-La Roche Ltd. Hypertension Drug Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.12 Gilead Sciences, Inc
6.12.1 Gilead Sciences, Inc Company Information
6.12.2 Gilead Sciences, Inc Description and Business Overview
6.12.3 Gilead Sciences, Inc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Gilead Sciences, Inc Hypertension Drug Product Portfolio
6.12.5 Gilead Sciences, Inc Recent Developments/Updates
6.13 HanAll Biopharma Co., Ltd
6.13.1 HanAll Biopharma Co., Ltd Company Information
6.13.2 HanAll Biopharma Co., Ltd Description and Business Overview
6.13.3 HanAll Biopharma Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 HanAll Biopharma Co., Ltd Hypertension Drug Product Portfolio
6.13.5 HanAll Biopharma Co., Ltd Recent Developments/Updates
6.14 Hanmi Pharmaceutical Co., Ltd
6.14.1 Hanmi Pharmaceutical Co., Ltd Company Information
6.14.2 Hanmi Pharmaceutical Co., Ltd Description and Business Overview
6.14.3 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product Portfolio
6.14.5 Hanmi Pharmaceutical Co., Ltd Recent Developments/Updates
6.15 Johnson & Johnson Ltd
6.15.1 Johnson & Johnson Ltd Company Information
6.15.2 Johnson & Johnson Ltd Description and Business Overview
6.15.3 Johnson & Johnson Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Johnson & Johnson Ltd Hypertension Drug Product Portfolio
6.15.5 Johnson & Johnson Ltd Recent Developments/Updates
6.16 JW Pharmaceutical Corporation (Choongwae Pharma)
6.16.1 JW Pharmaceutical Corporation (Choongwae Pharma) Company Information
6.16.2 JW Pharmaceutical Corporation (Choongwae Pharma) Description and Business Overview
6.16.3 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.16.4 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product Portfolio
6.16.5 JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments/Updates
6.17 Kyowa Kirin Co., Ltd
6.17.1 Kyowa Kirin Co., Ltd Company Information
6.17.2 Kyowa Kirin Co., Ltd Description and Business Overview
6.17.3 Kyowa Kirin Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Kyowa Kirin Co., Ltd Hypertension Drug Product Portfolio
6.17.5 Kyowa Kirin Co., Ltd Recent Developments/Updates
6.18 Lupin Limited
6.18.1 Lupin Limited Company Information
6.18.2 Lupin Limited Description and Business Overview
6.18.3 Lupin Limited Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Lupin Limited Hypertension Drug Product Portfolio
6.18.5 Lupin Limited Recent Developments/Updates
6.19 Merck & Co.
6.19.1 Merck & Co. Company Information
6.19.2 Merck & Co. Description and Business Overview
6.19.3 Merck & Co. Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Merck & Co. Hypertension Drug Product Portfolio
6.19.5 Merck & Co. Recent Developments/Updates
6.20 Noden Pharma DAC
6.20.1 Noden Pharma DAC Company Information
6.20.2 Noden Pharma DAC Description and Business Overview
6.20.3 Noden Pharma DAC Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Noden Pharma DAC Hypertension Drug Product Portfolio
6.20.5 Noden Pharma DAC Recent Developments/Updates
6.21 Novartis AG
6.21.1 Novartis AG Company Information
6.21.2 Novartis AG Description and Business Overview
6.21.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Novartis AG Hypertension Drug Product Portfolio
6.21.5 Novartis AG Recent Developments/Updates
6.22 Pfizer Inc
6.22.1 Pfizer Inc Company Information
6.22.2 Pfizer Inc Description and Business Overview
6.22.3 Pfizer Inc Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Pfizer Inc Hypertension Drug Product Portfolio
6.22.5 Pfizer Inc Recent Developments/Updates
6.23 Ranbaxy Laboratories Limited
6.23.1 Ranbaxy Laboratories Limited Company Information
6.23.2 Ranbaxy Laboratories Limited Description and Business Overview
6.23.3 Ranbaxy Laboratories Limited Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Ranbaxy Laboratories Limited Hypertension Drug Product Portfolio
6.23.5 Ranbaxy Laboratories Limited Recent Developments/Updates
6.24 Sanofi S.A
6.24.1 Sanofi S.A Company Information
6.24.2 Sanofi S.A Description and Business Overview
6.24.3 Sanofi S.A Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Sanofi S.A Hypertension Drug Product Portfolio
6.24.5 Sanofi S.A Recent Developments/Updates
6.25 Lung Biotechnology PBC
6.25.1 Lung Biotechnology PBC Company Information
6.25.2 Lung Biotechnology PBC Description and Business Overview
6.25.3 Lung Biotechnology PBC Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Lung Biotechnology PBC Hypertension Drug Product Portfolio
6.25.5 Lung Biotechnology PBC Recent Developments/Updates
6.26 Nippon Shinyaku Co. Ltd
6.26.1 Nippon Shinyaku Co. Ltd Company Information
6.26.2 Nippon Shinyaku Co. Ltd Description and Business Overview
6.26.3 Nippon Shinyaku Co. Ltd Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Nippon Shinyaku Co. Ltd Hypertension Drug Product Portfolio
6.26.5 Nippon Shinyaku Co. Ltd Recent Developments/Updates
6.27 Novartis AG
6.27.1 Novartis AG Company Information
6.27.2 Novartis AG Description and Business Overview
6.27.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.27.4 Novartis AG Hypertension Drug Product Portfolio
6.27.5 Novartis AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hypertension Drug Industry Chain Analysis
7.2 Hypertension Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hypertension Drug Production Mode & Process Analysis
7.4 Hypertension Drug Sales and Marketing
7.4.1 Hypertension Drug Sales Channels
7.4.2 Hypertension Drug Distributors
7.5 Hypertension Drug Customer Analysis
8 Hypertension Drug Market Dynamics
8.1 Hypertension Drug Industry Trends
8.2 Hypertension Drug Market Drivers
8.3 Hypertension Drug Market Challenges
8.4 Hypertension Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Hypertension Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Hypertension Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Hypertension Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Hypertension Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Hypertension Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Hypertension Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Hypertension Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Hypertension Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Hypertension Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Hypertension Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Hypertension Drug, Product Type & Application
Table 12. Global Key Manufacturers of Hypertension Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Hypertension Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Hypertension Drug Sales Market Share by Region (2020-2025)
Table 19. Global Hypertension Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Hypertension Drug Sales Market Share by Region (2026-2031)
Table 21. Global Hypertension Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Hypertension Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Hypertension Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Hypertension Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Hypertension Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Hypertension Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Hypertension Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Hypertension Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Hypertension Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Hypertension Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Hypertension Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Hypertension Drug Sales Market Share by Type (2020-2025)
Table 53. Global Hypertension Drug Sales Market Share by Type (2026-2031)
Table 54. Global Hypertension Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Hypertension Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Hypertension Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Hypertension Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Hypertension Drug Price (USD/Unit) by Type (2020-2025)
Table 59. Global Hypertension Drug Price (USD/Unit) by Type (2026-2031)
Table 60. Global Hypertension Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Hypertension Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Hypertension Drug Sales Market Share by Application (2020-2025)
Table 63. Global Hypertension Drug Sales Market Share by Application (2026-2031)
Table 64. Global Hypertension Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Hypertension Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Hypertension Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Hypertension Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Hypertension Drug Price (USD/Unit) by Application (2020-2025)
Table 69. Global Hypertension Drug Price (USD/Unit) by Application (2026-2031)
Table 70. Actelion Ltd. Company Information
Table 71. Actelion Ltd. Description and Business Overview
Table 72. Actelion Ltd. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Actelion Ltd. Hypertension Drug Product
Table 74. Actelion Ltd. Recent Developments/Updates
Table 75. Alvogen Company Information
Table 76. Alvogen Description and Business Overview
Table 77. Alvogen Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Alvogen Hypertension Drug Product
Table 79. Alvogen Recent Developments/Updates
Table 80. AstraZeneca Plc Company Information
Table 81. AstraZeneca Plc Description and Business Overview
Table 82. AstraZeneca Plc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Plc Hypertension Drug Product
Table 84. AstraZeneca Plc Recent Developments/Updates
Table 85. Bayer AG Company Information
Table 86. Bayer AG Description and Business Overview
Table 87. Bayer AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Bayer AG Hypertension Drug Product
Table 89. Bayer AG Recent Developments/Updates
Table 90. Bellerophon Therapeutics, Inc Company Information
Table 91. Bellerophon Therapeutics, Inc Description and Business Overview
Table 92. Bellerophon Therapeutics, Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Bellerophon Therapeutics, Inc Hypertension Drug Product
Table 94. Bellerophon Therapeutics, Inc Recent Developments/Updates
Table 95. Boehringer Ingelheim Company Information
Table 96. Boehringer Ingelheim Description and Business Overview
Table 97. Boehringer Ingelheim Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Boehringer Ingelheim Hypertension Drug Product
Table 99. Boehringer Ingelheim Recent Developments/Updates
Table 100. Boryung Pharmaceutical Co.,Ltd Company Information
Table 101. Boryung Pharmaceutical Co.,Ltd Description and Business Overview
Table 102. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product
Table 104. Boryung Pharmaceutical Co.,Ltd Recent Developments/Updates
Table 105. Bristol-Myers Squibb and Company, Company Information
Table 106. Bristol-Myers Squibb and Company, Description and Business Overview
Table 107. Bristol-Myers Squibb and Company, Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Bristol-Myers Squibb and Company, Hypertension Drug Product
Table 109. Bristol-Myers Squibb and Company, Recent Developments/Updates
Table 110. Daiichi Sankyo Company Company Information
Table 111. Daiichi Sankyo Company Description and Business Overview
Table 112. Daiichi Sankyo Company Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Daiichi Sankyo Company Hypertension Drug Product
Table 114. Daiichi Sankyo Company Recent Developments/Updates
Table 115. Eli Lilly and Company Company Information
Table 116. Eli Lilly and Company Description and Business Overview
Table 117. Eli Lilly and Company Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Eli Lilly and Company Hypertension Drug Product
Table 119. Eli Lilly and Company Recent Developments/Updates
Table 120. F. Hoffmann-La Roche Ltd. Company Information
Table 121. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 122. F. Hoffmann-La Roche Ltd. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. F. Hoffmann-La Roche Ltd. Hypertension Drug Product
Table 124. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 125. Gilead Sciences, Inc Company Information
Table 126. Gilead Sciences, Inc Description and Business Overview
Table 127. Gilead Sciences, Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Gilead Sciences, Inc Hypertension Drug Product
Table 129. Gilead Sciences, Inc Recent Developments/Updates
Table 130. HanAll Biopharma Co., Ltd Company Information
Table 131. HanAll Biopharma Co., Ltd Description and Business Overview
Table 132. HanAll Biopharma Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. HanAll Biopharma Co., Ltd Hypertension Drug Product
Table 134. HanAll Biopharma Co., Ltd Recent Developments/Updates
Table 135. Hanmi Pharmaceutical Co., Ltd Company Information
Table 136. Hanmi Pharmaceutical Co., Ltd Description and Business Overview
Table 137. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product
Table 139. Hanmi Pharmaceutical Co., Ltd Recent Developments/Updates
Table 140. Johnson & Johnson Ltd Company Information
Table 141. Johnson & Johnson Ltd Description and Business Overview
Table 142. Johnson & Johnson Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Johnson & Johnson Ltd Hypertension Drug Product
Table 144. Johnson & Johnson Ltd Recent Developments/Updates
Table 145. JW Pharmaceutical Corporation (Choongwae Pharma) Company Information
Table 146. JW Pharmaceutical Corporation (Choongwae Pharma) Description and Business Overview
Table 147. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 148. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product
Table 149. JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments/Updates
Table 150. Kyowa Kirin Co., Ltd Company Information
Table 151. Kyowa Kirin Co., Ltd Description and Business Overview
Table 152. Kyowa Kirin Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 153. Kyowa Kirin Co., Ltd Hypertension Drug Product
Table 154. Kyowa Kirin Co., Ltd Recent Developments/Updates
Table 155. Lupin Limited Company Information
Table 156. Lupin Limited Description and Business Overview
Table 157. Lupin Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 158. Lupin Limited Hypertension Drug Product
Table 159. Lupin Limited Recent Developments/Updates
Table 160. Merck & Co. Company Information
Table 161. Merck & Co. Description and Business Overview
Table 162. Merck & Co. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 163. Merck & Co. Hypertension Drug Product
Table 164. Merck & Co. Recent Developments/Updates
Table 165. Noden Pharma DAC Company Information
Table 166. Noden Pharma DAC Description and Business Overview
Table 167. Noden Pharma DAC Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 168. Noden Pharma DAC Hypertension Drug Product
Table 169. Noden Pharma DAC Recent Developments/Updates
Table 170. Novartis AG Company Information
Table 171. Novartis AG Description and Business Overview
Table 172. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 173. Novartis AG Hypertension Drug Product
Table 174. Novartis AG Recent Developments/Updates
Table 175. Pfizer Inc Company Information
Table 176. Pfizer Inc Description and Business Overview
Table 177. Pfizer Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 178. Pfizer Inc Hypertension Drug Product
Table 179. Pfizer Inc Recent Developments/Updates
Table 180. Ranbaxy Laboratories Limited Company Information
Table 181. Ranbaxy Laboratories Limited Description and Business Overview
Table 182. Ranbaxy Laboratories Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 183. Ranbaxy Laboratories Limited Hypertension Drug Product
Table 184. Ranbaxy Laboratories Limited Recent Developments/Updates
Table 185. Sanofi S.A Company Information
Table 186. Sanofi S.A Description and Business Overview
Table 187. Sanofi S.A Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 188. Sanofi S.A Hypertension Drug Product
Table 189. Sanofi S.A Recent Developments/Updates
Table 190. Lung Biotechnology PBC Company Information
Table 191. Lung Biotechnology PBC Description and Business Overview
Table 192. Lung Biotechnology PBC Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 193. Lung Biotechnology PBC Hypertension Drug Product
Table 194. Lung Biotechnology PBC Recent Developments/Updates
Table 195. Nippon Shinyaku Co. Ltd Company Information
Table 196. Nippon Shinyaku Co. Ltd Description and Business Overview
Table 197. Nippon Shinyaku Co. Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 198. Nippon Shinyaku Co. Ltd Hypertension Drug Product
Table 199. Nippon Shinyaku Co. Ltd Recent Developments/Updates
Table 200. Novartis AG Company Information
Table 201. Novartis AG Description and Business Overview
Table 202. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 203. Novartis AG Hypertension Drug Product
Table 204. Novartis AG Recent Developments/Updates
Table 205. Key Raw Materials Lists
Table 206. Raw Materials Key Suppliers Lists
Table 207. Hypertension Drug Distributors List
Table 208. Hypertension Drug Customers List
Table 209. Hypertension Drug Market Trends
Table 210. Hypertension Drug Market Drivers
Table 211. Hypertension Drug Market Challenges
Table 212. Hypertension Drug Market Restraints
Table 213. Research Programs/Design for This Report
Table 214. Key Data Information from Secondary Sources
Table 215. Key Data Information from Primary Sources
Table 216. Authors List of This Report
List of Figures
Figure 1. Product Picture of Hypertension Drug
Figure 2. Global Hypertension Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Hypertension Drug Market Share by Type: 2024 & 2031
Figure 4. Calcium Channel Blockers Product Picture
Figure 5. Diuretics Product Picture
Figure 6. Beta Blockers Vasodilators Product Picture
Figure 7. Angiotensin Converting Enzyme Inhibitors Product Picture
Figure 8. Alpha Blockers Product Picture
Figure 9. Angiotensin Receptor Blockers Product Picture
Figure 10. Renin Inhibitors Product Picture
Figure 11. Global Hypertension Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 12. Global Hypertension Drug Market Share by Application: 2024 & 2031
Figure 13. Hospital
Figure 14. Private Clinic
Figure 15. Others
Figure 16. Global Hypertension Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Hypertension Drug Market Size (2020-2031) & (US$ Million)
Figure 18. Global Hypertension Drug Sales (2020-2031) & (K Units)
Figure 19. Global Hypertension Drug Average Price (USD/Unit) & (2020-2031)
Figure 20. Hypertension Drug Report Years Considered
Figure 21. Hypertension Drug Sales Share by Manufacturers in 2024
Figure 22. Global Hypertension Drug Revenue Share by Manufacturers in 2024
Figure 23. Global 5 and 10 Largest Hypertension Drug Players: Market Share by Revenue in Hypertension Drug in 2024
Figure 24. Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. Global Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 26. North America Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 27. North America Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 28. U.S. Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Canada Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Europe Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 31. Europe Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 32. Germany Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Russia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Hypertension Drug Sales Market Share by Region (2020-2031)
Figure 38. Asia Pacific Hypertension Drug Revenue Market Share by Region (2020-2031)
Figure 39. China Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Taiwan Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Indonesia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Thailand Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Malaysia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Philippines Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Latin America Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 50. Latin America Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Middle East and Africa Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 55. Middle East and Africa Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 56. Turkey Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Saudi Arabia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. U.A.E Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. Global Sales Market Share of Hypertension Drug by Type (2020-2031)
Figure 60. Global Revenue Market Share of Hypertension Drug by Type (2020-2031)
Figure 61. Global Hypertension Drug Price (USD/Unit) by Type (2020-2031)
Figure 62. Global Sales Market Share of Hypertension Drug by Application (2020-2031)
Figure 63. Global Revenue Market Share of Hypertension Drug by Application (2020-2031)
Figure 64. Global Hypertension Drug Price (USD/Unit) by Application (2020-2031)
Figure 65. Hypertension Drug Value Chain
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Hypertension Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Hypertension Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Hypertension Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Hypertension Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Hypertension Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Hypertension Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Hypertension Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Hypertension Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Hypertension Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Hypertension Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Hypertension Drug, Product Type & Application
Table 12. Global Key Manufacturers of Hypertension Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Hypertension Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Hypertension Drug Sales Market Share by Region (2020-2025)
Table 19. Global Hypertension Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Hypertension Drug Sales Market Share by Region (2026-2031)
Table 21. Global Hypertension Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Hypertension Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Hypertension Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Hypertension Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Hypertension Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Hypertension Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Hypertension Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Hypertension Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Hypertension Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Hypertension Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Hypertension Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Hypertension Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Hypertension Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Hypertension Drug Sales Market Share by Type (2020-2025)
Table 53. Global Hypertension Drug Sales Market Share by Type (2026-2031)
Table 54. Global Hypertension Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Hypertension Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Hypertension Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Hypertension Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Hypertension Drug Price (USD/Unit) by Type (2020-2025)
Table 59. Global Hypertension Drug Price (USD/Unit) by Type (2026-2031)
Table 60. Global Hypertension Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Hypertension Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Hypertension Drug Sales Market Share by Application (2020-2025)
Table 63. Global Hypertension Drug Sales Market Share by Application (2026-2031)
Table 64. Global Hypertension Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Hypertension Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Hypertension Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Hypertension Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Hypertension Drug Price (USD/Unit) by Application (2020-2025)
Table 69. Global Hypertension Drug Price (USD/Unit) by Application (2026-2031)
Table 70. Actelion Ltd. Company Information
Table 71. Actelion Ltd. Description and Business Overview
Table 72. Actelion Ltd. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Actelion Ltd. Hypertension Drug Product
Table 74. Actelion Ltd. Recent Developments/Updates
Table 75. Alvogen Company Information
Table 76. Alvogen Description and Business Overview
Table 77. Alvogen Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Alvogen Hypertension Drug Product
Table 79. Alvogen Recent Developments/Updates
Table 80. AstraZeneca Plc Company Information
Table 81. AstraZeneca Plc Description and Business Overview
Table 82. AstraZeneca Plc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Plc Hypertension Drug Product
Table 84. AstraZeneca Plc Recent Developments/Updates
Table 85. Bayer AG Company Information
Table 86. Bayer AG Description and Business Overview
Table 87. Bayer AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Bayer AG Hypertension Drug Product
Table 89. Bayer AG Recent Developments/Updates
Table 90. Bellerophon Therapeutics, Inc Company Information
Table 91. Bellerophon Therapeutics, Inc Description and Business Overview
Table 92. Bellerophon Therapeutics, Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Bellerophon Therapeutics, Inc Hypertension Drug Product
Table 94. Bellerophon Therapeutics, Inc Recent Developments/Updates
Table 95. Boehringer Ingelheim Company Information
Table 96. Boehringer Ingelheim Description and Business Overview
Table 97. Boehringer Ingelheim Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Boehringer Ingelheim Hypertension Drug Product
Table 99. Boehringer Ingelheim Recent Developments/Updates
Table 100. Boryung Pharmaceutical Co.,Ltd Company Information
Table 101. Boryung Pharmaceutical Co.,Ltd Description and Business Overview
Table 102. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product
Table 104. Boryung Pharmaceutical Co.,Ltd Recent Developments/Updates
Table 105. Bristol-Myers Squibb and Company, Company Information
Table 106. Bristol-Myers Squibb and Company, Description and Business Overview
Table 107. Bristol-Myers Squibb and Company, Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Bristol-Myers Squibb and Company, Hypertension Drug Product
Table 109. Bristol-Myers Squibb and Company, Recent Developments/Updates
Table 110. Daiichi Sankyo Company Company Information
Table 111. Daiichi Sankyo Company Description and Business Overview
Table 112. Daiichi Sankyo Company Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Daiichi Sankyo Company Hypertension Drug Product
Table 114. Daiichi Sankyo Company Recent Developments/Updates
Table 115. Eli Lilly and Company Company Information
Table 116. Eli Lilly and Company Description and Business Overview
Table 117. Eli Lilly and Company Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Eli Lilly and Company Hypertension Drug Product
Table 119. Eli Lilly and Company Recent Developments/Updates
Table 120. F. Hoffmann-La Roche Ltd. Company Information
Table 121. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 122. F. Hoffmann-La Roche Ltd. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. F. Hoffmann-La Roche Ltd. Hypertension Drug Product
Table 124. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 125. Gilead Sciences, Inc Company Information
Table 126. Gilead Sciences, Inc Description and Business Overview
Table 127. Gilead Sciences, Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Gilead Sciences, Inc Hypertension Drug Product
Table 129. Gilead Sciences, Inc Recent Developments/Updates
Table 130. HanAll Biopharma Co., Ltd Company Information
Table 131. HanAll Biopharma Co., Ltd Description and Business Overview
Table 132. HanAll Biopharma Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. HanAll Biopharma Co., Ltd Hypertension Drug Product
Table 134. HanAll Biopharma Co., Ltd Recent Developments/Updates
Table 135. Hanmi Pharmaceutical Co., Ltd Company Information
Table 136. Hanmi Pharmaceutical Co., Ltd Description and Business Overview
Table 137. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product
Table 139. Hanmi Pharmaceutical Co., Ltd Recent Developments/Updates
Table 140. Johnson & Johnson Ltd Company Information
Table 141. Johnson & Johnson Ltd Description and Business Overview
Table 142. Johnson & Johnson Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Johnson & Johnson Ltd Hypertension Drug Product
Table 144. Johnson & Johnson Ltd Recent Developments/Updates
Table 145. JW Pharmaceutical Corporation (Choongwae Pharma) Company Information
Table 146. JW Pharmaceutical Corporation (Choongwae Pharma) Description and Business Overview
Table 147. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 148. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product
Table 149. JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments/Updates
Table 150. Kyowa Kirin Co., Ltd Company Information
Table 151. Kyowa Kirin Co., Ltd Description and Business Overview
Table 152. Kyowa Kirin Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 153. Kyowa Kirin Co., Ltd Hypertension Drug Product
Table 154. Kyowa Kirin Co., Ltd Recent Developments/Updates
Table 155. Lupin Limited Company Information
Table 156. Lupin Limited Description and Business Overview
Table 157. Lupin Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 158. Lupin Limited Hypertension Drug Product
Table 159. Lupin Limited Recent Developments/Updates
Table 160. Merck & Co. Company Information
Table 161. Merck & Co. Description and Business Overview
Table 162. Merck & Co. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 163. Merck & Co. Hypertension Drug Product
Table 164. Merck & Co. Recent Developments/Updates
Table 165. Noden Pharma DAC Company Information
Table 166. Noden Pharma DAC Description and Business Overview
Table 167. Noden Pharma DAC Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 168. Noden Pharma DAC Hypertension Drug Product
Table 169. Noden Pharma DAC Recent Developments/Updates
Table 170. Novartis AG Company Information
Table 171. Novartis AG Description and Business Overview
Table 172. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 173. Novartis AG Hypertension Drug Product
Table 174. Novartis AG Recent Developments/Updates
Table 175. Pfizer Inc Company Information
Table 176. Pfizer Inc Description and Business Overview
Table 177. Pfizer Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 178. Pfizer Inc Hypertension Drug Product
Table 179. Pfizer Inc Recent Developments/Updates
Table 180. Ranbaxy Laboratories Limited Company Information
Table 181. Ranbaxy Laboratories Limited Description and Business Overview
Table 182. Ranbaxy Laboratories Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 183. Ranbaxy Laboratories Limited Hypertension Drug Product
Table 184. Ranbaxy Laboratories Limited Recent Developments/Updates
Table 185. Sanofi S.A Company Information
Table 186. Sanofi S.A Description and Business Overview
Table 187. Sanofi S.A Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 188. Sanofi S.A Hypertension Drug Product
Table 189. Sanofi S.A Recent Developments/Updates
Table 190. Lung Biotechnology PBC Company Information
Table 191. Lung Biotechnology PBC Description and Business Overview
Table 192. Lung Biotechnology PBC Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 193. Lung Biotechnology PBC Hypertension Drug Product
Table 194. Lung Biotechnology PBC Recent Developments/Updates
Table 195. Nippon Shinyaku Co. Ltd Company Information
Table 196. Nippon Shinyaku Co. Ltd Description and Business Overview
Table 197. Nippon Shinyaku Co. Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 198. Nippon Shinyaku Co. Ltd Hypertension Drug Product
Table 199. Nippon Shinyaku Co. Ltd Recent Developments/Updates
Table 200. Novartis AG Company Information
Table 201. Novartis AG Description and Business Overview
Table 202. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 203. Novartis AG Hypertension Drug Product
Table 204. Novartis AG Recent Developments/Updates
Table 205. Key Raw Materials Lists
Table 206. Raw Materials Key Suppliers Lists
Table 207. Hypertension Drug Distributors List
Table 208. Hypertension Drug Customers List
Table 209. Hypertension Drug Market Trends
Table 210. Hypertension Drug Market Drivers
Table 211. Hypertension Drug Market Challenges
Table 212. Hypertension Drug Market Restraints
Table 213. Research Programs/Design for This Report
Table 214. Key Data Information from Secondary Sources
Table 215. Key Data Information from Primary Sources
Table 216. Authors List of This Report
List of Figures
Figure 1. Product Picture of Hypertension Drug
Figure 2. Global Hypertension Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Hypertension Drug Market Share by Type: 2024 & 2031
Figure 4. Calcium Channel Blockers Product Picture
Figure 5. Diuretics Product Picture
Figure 6. Beta Blockers Vasodilators Product Picture
Figure 7. Angiotensin Converting Enzyme Inhibitors Product Picture
Figure 8. Alpha Blockers Product Picture
Figure 9. Angiotensin Receptor Blockers Product Picture
Figure 10. Renin Inhibitors Product Picture
Figure 11. Global Hypertension Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 12. Global Hypertension Drug Market Share by Application: 2024 & 2031
Figure 13. Hospital
Figure 14. Private Clinic
Figure 15. Others
Figure 16. Global Hypertension Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Hypertension Drug Market Size (2020-2031) & (US$ Million)
Figure 18. Global Hypertension Drug Sales (2020-2031) & (K Units)
Figure 19. Global Hypertension Drug Average Price (USD/Unit) & (2020-2031)
Figure 20. Hypertension Drug Report Years Considered
Figure 21. Hypertension Drug Sales Share by Manufacturers in 2024
Figure 22. Global Hypertension Drug Revenue Share by Manufacturers in 2024
Figure 23. Global 5 and 10 Largest Hypertension Drug Players: Market Share by Revenue in Hypertension Drug in 2024
Figure 24. Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. Global Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 26. North America Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 27. North America Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 28. U.S. Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Canada Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Europe Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 31. Europe Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 32. Germany Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Russia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Hypertension Drug Sales Market Share by Region (2020-2031)
Figure 38. Asia Pacific Hypertension Drug Revenue Market Share by Region (2020-2031)
Figure 39. China Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Taiwan Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Indonesia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Thailand Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Malaysia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Philippines Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Latin America Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 50. Latin America Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Middle East and Africa Hypertension Drug Sales Market Share by Country (2020-2031)
Figure 55. Middle East and Africa Hypertension Drug Revenue Market Share by Country (2020-2031)
Figure 56. Turkey Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Saudi Arabia Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. U.A.E Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. Global Sales Market Share of Hypertension Drug by Type (2020-2031)
Figure 60. Global Revenue Market Share of Hypertension Drug by Type (2020-2031)
Figure 61. Global Hypertension Drug Price (USD/Unit) by Type (2020-2031)
Figure 62. Global Sales Market Share of Hypertension Drug by Application (2020-2031)
Figure 63. Global Revenue Market Share of Hypertension Drug by Application (2020-2031)
Figure 64. Global Hypertension Drug Price (USD/Unit) by Application (2020-2031)
Figure 65. Hypertension Drug Value Chain
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232